New drug combo for AML after venetoclax failure
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new combination of drugs (lisafotoclax, decitabine, and homoharringtonine) for people with AML who have already tried venetoclax and azacitidine and it didn’t work. The goal is to find a treatment that might work when the first therapy fails.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have acute myeloid leukemia (AML), but not the APL subtype.
- You have already tried treatment with venetoclax and azacitidine and it either didn’t work or caused serious side effects.
- Your daily activity level is good (able to do light work or care for yourself).
- Your liver, kidneys, and heart are working well enough for the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of four drugs (venetoclax, homoharringtonine, azacitidine, and G-CSF) for people with newly diagnosed AML who cannot tolerate standard intensive chemotherapy. The goal is to see if this lower-intensity therapy can effectively treat the leukemia with fewer side effects.
This trial tests a combination of three drugs (cladribine, low-dose cytarabine, and venetoclax) for people with AML that has not responded to standard treatment, particularly if they have already taken venetoclax. The goal is to see if this new combination can help control the leukemia.
This trial compares a new combination of drugs (venetoclax, azacitidine, and liposomal mitoxantrone) against a standard chemotherapy regimen (idarubicin and cytarabine) for people with newly diagnosed acute myeloid leukemia (AML). It tests whether the new combination works better and is safe.
This trial tests a combination of two drugs, azacitidine and venetoclax, for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy but still have tiny amounts of leukemia cells left (measurable residual disease). The goal is to see if this treatment can clear those remaining cells before a stem cell transplant.
This trial tests a combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a donor stem cell transplant for people with intermediate- or high-risk acute myeloid leukemia (AML). The goal is to see if this approach can improve outcomes for patients who have not been treated before.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.